| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Tightens/Raises Mid-Point of Full Year 2025; Implies Fourth Quarter 2025 Outlook1
Mr. Bagan continued, "We have consistently delivered on our expectations for eight consecutive quarters, instilled a discipline of accountability across the organization, and are encouraged with the growing funnel of opportunities our go-to-market strategy is building. We are in a position to exceed the mid-point of the original full year outlook we established at the beginning of this year in spite of the tariff headwinds and divestiture of the CFP business. The team is demonstrating the resiliency and adaptability needed in an ever fluctuating backdrop of geopolitical conditions."
FY24 Actual
| Previous FY25 Outlook (issued 8/4/2025) | New FY25 Outlook (issued 11/3/25) | 4Q25 Outlook (issued 11/3/25) | |
| Total Net Sales | $805.9 million | $810 to $830 million | $820 to $830 million | $192 to $202 million |
| Adjusted EBITDA margin | 19.2% | 18.5% to 19.5% | 19.1% to 19.4% | 20.0% to 21.0% |
| Diluted Non-GAAP EPS | $2.10 | $2.30 to $2.50 | $2.43 to $2.50 | $0.67 to $0.74 |
| 1 Reference "Third Quarter 2025 Earnings Presentation" Slides for details and assumptions |
Posted In: HLIO
